About Neuralstem (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:CUR
- CUSIP: N/A
- Web: www.neuralstem.com
Capitalization:- Market Cap: $16.24 million
- Outstanding Shares: 12,117,000
Average Prices:- 50 Day Moving Avg: $1.28
- 200 Day Moving Avg: $3.35
- 52 Week Range: $0.22 - $6.60
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $16,246.00
- Price / Sales: 1,059.10
- Book Value: $0.64 per share
- Price / Book: 2.22
Profitability:- EBITDA: ($18,670,000.00)
- Net Margins: -198,573.91%
- Return on Equity: -321.78%
- Return on Assets: -127.53%
Debt:- Current Ratio: 5.08%
- Quick Ratio: 5.08%
Misc:- Average Volume: 681,603 shs.
- Beta: 1.78
- Short Ratio: 2.34
Frequently Asked Questions for Neuralstem (NASDAQ:CUR)
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) released its earnings results on Tuesday, August, 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%. View Neuralstem's Earnings History.
When will Neuralstem make its next earnings announcement?
Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?
2 brokers have issued 1 year price objectives for Neuralstem's shares. Their forecasts range from $1.20 to $3.18. On average, they expect Neuralstem's share price to reach $2.19 in the next twelve months. View Analyst Ratings for Neuralstem.
Are investors shorting Neuralstem?
Neuralstem saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 479,425 shares, a decrease of 46.1% from the September 15th total of 888,788 shares. Based on an average daily trading volume, of 1,367,130 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.1% of the shares of the company are short sold.
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include Pernix Therapeutics Holdings (PTX), Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Galena Biopharma (GALE), Immune Pharmaceuticals (IMNP), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), CannTrust Holdings (TRST), CoLucid Pharmaceuticals (CLCD), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK), Innocoll Holdings PLC (INNL), Optimer Pharmaceuticals (OPTR) and Questcor Pharmaceuticals (QCOR).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer
- Cristina Csimma, Director
- Zhuo Zhang, Director
- Scott V. Ogilvie, Independent Director
- William Clyde Oldaker, Independent Director
- Sandford D. Smith, Independent Director
How do I buy Neuralstem stock?
Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of Neuralstem stock can currently be purchased for approximately $1.42.
MarketBeat Community Rating for Neuralstem (NASDAQ CUR)MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Neuralstem (NASDAQ:CUR)Earnings History by Quarter for Neuralstem (NASDAQ CUR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.50) | | | | | N/A |  |
| 8/8/2017 | Q2 2017 | ($9.49) | ($0.39) | | | View | N/A | |
| 11/8/2016 | Q3 | ($0.03) | ($0.05) | | | View | N/A | |
| 8/11/2016 | Q2 | ($0.05) | ($0.04) | $2.50 million | $2.50 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.06) | ($0.07) | | | View | N/A | |
| 3/14/2016 | Q4 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/9/2015 | Q315 | ($0.07) | ($0.06) | | | View | N/A | |
| 8/10/2015 | Q2 | ($0.06) | ($0.06) | | | View | N/A | |
| 5/8/2015 | Q115 | ($0.07) | ($0.06) | | $2.92 million | View | N/A | |
| 4/20/2015 | | ($0.07) | ($0.06) | | | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.05) | ($0.06) | | $0.01 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.05) | ($0.05) | | $0.01 million | View | N/A | |
| 8/8/2014 | Q214 | ($0.05) | ($0.08) | $0.10 million | $0.01 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.04) | $0.35 million | $0.00 million | View | N/A | |
| 3/10/2014 | Q4 2013 | ($0.06) | ($0.04) | | | View | N/A | |
| 11/11/2013 | Q3 | ($0.04) | ($0.09) | | | View | N/A | |
| 8/9/2013 | Q213 | ($0.05) | ($0.09) | $0.08 million | $0.00 million | View | N/A | |
| 11/9/2012 | Q312 | ($0.04) | ($0.04) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Neuralstem (NASDAQ:CUR)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ:CUR)Insider Ownership Percentage: 19.25%
Institutional Ownership Percentage: 7.33%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/17/2017 | Richard J Daly | CEO | Buy | 7,500 | $4.00 | $30,000.00 | |
| 3/24/2017 | Jones Jonathan Brian Lloyd | CFO | Buy | 5,455 | $5.50 | $30,002.50 | |
| 2/24/2017 | Richard J Daly | CEO | Buy | 2,591 | $3.86 | $10,001.26 | |
| 1/25/2017 | Richard J Daly | CEO | Buy | 2,841 | $3.52 | $10,000.32 | |
| 12/23/2016 | Richard J Daly | CEO | Buy | 32,259 | $0.31 | $10,000.29 | |
| 11/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | |
| 10/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | |
| 9/23/2016 | Richard J Daly | CEO | Buy | 31,250 | $0.32 | $10,000.00 | |
| 11/16/2015 | Karl Johe | Insider | Sell | 25,000 | $1.09 | $27,250.00 | |
| 11/9/2015 | Karl Johe | Insider | Sell | 25,000 | $1.18 | $29,500.00 | |
| 11/2/2015 | Karl Johe | Insider | Sell | 25,000 | $1.17 | $29,250.00 | |
| 10/26/2015 | Karl Johe | Insider | Sell | 25,000 | $1.13 | $28,250.00 | |
| 10/19/2015 | Karl Johe | Insider | Sell | 25,000 | $1.23 | $30,750.00 | |
| 10/12/2015 | Karl Johe | Insider | Sell | 25,000 | $1.31 | $32,750.00 | |
| 10/5/2015 | Karl Johe | Insider | Sell | 25,000 | $1.26 | $31,500.00 | |
| 9/28/2015 | Karl Johe | Insider | Sell | 25,000 | $1.64 | $41,000.00 | |
| 9/21/2015 | Karl Johe | Insider | Sell | 25,000 | $1.52 | $38,000.00 | |
| 9/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.09 | $24,540.00 | |
| 8/1/2014 | Karl Johe | Insider | Sell | 6,000 | $2.78 | $16,680.00 | |
| 7/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.17 | $25,020.00 | |
| 6/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.25 | $25,500.00 | |
| 5/5/2014 | William Clyde Oldaker | Director | Buy | 15,235 | $3.50 | $53,322.50 | |
| 4/22/2014 | Richard Garr | CEO | Sell | 7,000 | $4.25 | $29,750.00 | |
| 4/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.11 | $24,660.00 | |
| 3/20/2014 | Karl Johe | Insider | Sell | 6,000 | $4.04 | $24,240.00 | |
| 10/18/2013 | Karl Johe | Insider | Sell | 10,000 | $2.44 | $24,400.00 | |
| 9/20/2013 | Karl Johe | Insider | Sell | 10,000 | $2.62 | $26,200.00 | |
| 9/19/2013 | Karl Johe | Insider | Sell | 10,000 | $2.61 | $26,100.00 | |
| 8/20/2013 | Karl Johe | Insider | Sell | 20,000 | $1.55 | $31,000.00 | |
| 7/22/2013 | Karl Johe | Insider | Sell | 12,800 | $1.62 | $20,736.00 | |
| 6/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.40 | $17,920.00 | |
| 6/7/2013 | Richard Garr | CEO | Sell | 6,000 | $1.42 | $8,520.00 | |
| 5/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.51 | $19,328.00 | |
| 2/25/2013 | Richard Garr | CEO | Sell | 12,000 | $1.15 | $13,800.00 | |
| 11/20/2012 | Karl Johe | Insider | Sell | 12,800 | $1.00 | $12,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Neuralstem (NASDAQ:CUR)
Latest Headlines for Neuralstem (NASDAQ:CUR)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Analysis: Neos Therapeutics (NEOS) and Neuralstem (CUR)
www.americanbankingnews.com - October 20 at 2:10 PM |
 | One Thing To Consider Before Buying Neuralstem Inc (CUR)
finance.yahoo.com - October 17 at 6:24 PM |
| Neuralstem, Inc. (CUR) Sees Large Drop in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM |
| Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells
finance.yahoo.com - October 3 at 6:56 AM |
| Neuralstem Announces the Appointment of Two New Members to the Board of Directors
finance.yahoo.com - September 25 at 4:08 PM |
| ETFs with exposure to Neuralstem, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:41 PM |
| ETFs with exposure to Neuralstem, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 11:28 PM |
 | Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.com
www.thestreet.com - September 7 at 10:45 PM |
 | Neuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.com
www.streetinsider.com - September 7 at 10:45 PM |
| Neuralstem (CUR) Reports Issuance of Two U.S. Patents
www.streetinsider.com - September 7 at 5:44 PM |
| Neuralstem Announces Issuance of Two U.S. Patents
finance.yahoo.com - September 7 at 5:44 PM |
| ETFs with exposure to Neuralstem, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:34 PM |
| Neuralstem, Inc. (CUR) Short Interest Update
www.americanbankingnews.com - August 29 at 1:06 AM |
| Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:51 PM |
| Head-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - August 22 at 8:26 PM |
| Neuralstem, Inc. (CUR) Issues Earnings Results, Beats Expectations By $9.10 EPS
www.americanbankingnews.com - August 9 at 5:54 PM |
 | Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
www.nasdaq.com - August 8 at 10:21 PM |
| Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - August 8 at 5:20 PM |
| Neuralstem reports 2Q loss
finance.yahoo.com - August 8 at 5:20 PM |
 | Neuralstem Is Doomed - Neuralstem, Inc. (NYSEMKT:CUR ... - Seeking Alpha
seekingalpha.com - August 3 at 7:03 PM |
 | Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 11:34 PM |
| Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - Nasdaq
www.nasdaq.com - August 2 at 6:32 PM |
| Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
finance.yahoo.com - August 2 at 6:32 PM |
 | Mid-Day Market Update: ShoreTel Gains On Acquisition News ... - Benzinga
www.benzinga.com - July 28 at 7:29 PM |
| Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge
www.nasdaq.com - July 27 at 5:59 PM |
| Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - July 27 at 5:59 PM |
| Neuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy Endpoint
www.nasdaq.com - July 27 at 2:20 AM |
| After-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)
www.streetinsider.com - July 27 at 2:20 AM |
| Today's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma
finance.yahoo.com - July 26 at 6:13 PM |
| Neuralstem Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - July 26 at 6:13 PM |
 | Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX
www.rttnews.com - July 26 at 3:43 AM |
| Mid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - Benzinga
www.benzinga.com - July 25 at 10:39 PM |
 | UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatch
www.marketwatch.com - July 25 at 10:39 PM |
| Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
finance.yahoo.com - July 25 at 5:37 PM |
| UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss
finance.yahoo.com - July 25 at 5:37 PM |
| ETFs with exposure to Neuralstem, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 12:22 AM |
| Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM |
| Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM |
 | Gainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...
www.finanznachrichten.de - May 11 at 2:49 AM |
| Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
globenewswire.com - May 10 at 4:47 PM |
| Neuralstem, Inc. (CUR)
seekingalpha.com - May 4 at 9:45 PM |
 | BioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development
www.businesswire.com - April 20 at 4:45 PM |
| Neuralstem (CUR) Adds Four Cohorts to Ongoing Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury - StreetInsider.com
www.streetinsider.com - April 13 at 11:48 AM |
| NEURALSTEM, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 23 at 5:09 PM |
 | Neuralstem Reports Year End 2016 Fiscal Results and Business Update
us.rd.yahoo.com - March 23 at 5:09 PM |
| Neuralstem (CUR) Reports Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - StreetInsider.com
www.streetinsider.com - March 11 at 10:09 AM |
| Today's Research Reports on Market Movers: Neuralstem and Real Goods Solar
us.rd.yahoo.com - March 10 at 5:39 PM |
| Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
us.rd.yahoo.com - March 9 at 5:11 PM |
| Neuralstem to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 10:20 PM |
| Neuralstem (CUR) Announces Publication of NSI-189 Preclinical Data
www.streetinsider.com - March 1 at 1:18 PM |
Neuralstem (CUR) Chart for Saturday, October, 21, 2017
